BRAF and melanoma: Despite the discouraging efficacy data of front-line treatment observed in our cohort of BRAF-mutant melanoma patients, overall survival in our cohort was comparable to previous RCTs, with a median OS of 33.0 months compared to 45.5 months for first-line pembrolizumab monotherapy [26] and a median OS of 25.9 and 33.6 months being reported for COMBI-d [5] and the COLUMBUS trial [7], respectively.